MARKET WIRE NEWS

Grifols: Reassuring Evidence, Still On The Sidelines

Source: SeekingAlpha

2025-07-18 07:05:40 ET

We return to Grifols ( GRFS ) with a fresh review, following our previously neutral stance, which reflected a balance of encouraging progress and lingering concerns. As a reminder, we reported many question marks , and even if the company's leverage and governance concerns were addressed, we still saw a red flag on negligible FCF generation. While Grifols' share price has rebounded (Fig. 1) — highlighting a missed opportunity on our part — we believe it's still appropriate to note the ongoing presence of short-seller scrutiny and unresolved litigation risks ....

Read the full article on Seeking Alpha

For further details see:

Grifols: Reassuring Evidence, Still On The Sidelines
Grifols S.A.

NASDAQ: GRFS

GRFS Trading

-3.13% G/L:

$8.055 Last:

499,195 Volume:

$8.19 Open:

mwn-ir Ad 300

GRFS Latest News

February 25, 2026 04:30:59 am
Expected earnings - Grifols S.A.
March 10, 2025 12:28:00 pm
How To Trade (GRFS)

GRFS Stock Data

$6,538,647,175
559,676,571
N/A
69
N/A
Pharmaceuticals
Healthcare
ES
Sant Cugat del Valles

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App